ANI Pharmaceuticals, Inc. (ANIP) Earnings Call Analysis
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Next earnings call: 2026-08-07
(Q2 2026)
— full calendar
Earnings Reports
-
ANI Pharmaceuticals (ANIP) Q1 2026: Cortrophin Gel Jumps 42% as Rare Disease Mix Hits 60%
May 08, 2026
-
ANI Pharmaceuticals (ANIP) Q4 2025: Rare Disease Revenue to Reach 60% of $1B+ Sales in 2026
February 27, 2026
-
ANI Pharmaceuticals (ANIP) Q3 2025: Rare Disease Revenue Surges 110%, Fueling Guidance Raise
November 07, 2025
-
ANI Pharmaceuticals (ANIP) Q2 2025: Cortrophin Gel Guidance Raised 21% as Rare Disease Momentum Accelerates
August 08, 2025
-
ANI Pharmaceuticals (ANIP) Q1 2025: Rare Disease Revenue Jumps 87% as Cortrophin Gel Expands Market Reach
July 06, 2025
-
ANI Pharmaceuticals (ANIP) Q3 2024: Rare Disease Now 77% Growth Engine as Alimera Integration Targets $10M Synergy
November 08, 2024
-
ANI Pharmaceuticals (ANIP) Q2 2024: Cortrophin Gel Revenues Double, Rare Disease Now 45% of Pro Forma Sales
August 06, 2024
-
ANI Pharmaceuticals (ANIP) Q1 2024: Cortrophin Gel Revenue Soars 126% as Rare Disease Platform Broadens
May 10, 2024
-
ANI Pharmaceuticals (ANIP) Q4 2023: Cortrophin Gel Jumps 137% as Rare Disease Expansion Accelerates
February 29, 2024